Our lead asset, OBT076, is an innovative Antibody Drug Conjugate (ADC) with a potential dual mechanism of action.
OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients. The CD205 receptor is highly overexpressed in solid and liquid tumors with high unmet need including gastric, lung and ovarian cancer.
OBT076 is demonstrating activity as a monotherapy. In addition, OBT076 can also act as a ‘primer’ re-engaging the patient’s immune system while at the same time targeting cancer cells.
A maximum tolerated dose has been determined for OBT076 and the asset has shown promising early signs of clinical activity. It is currently being evaluated in Phase 1b expansion cohorts in multiple solid tumor indications. OBT is also planning combination trials for OBT076.
OBT is responsible for the full development, approval and commercialization of OBT076 in North America and Japan. For oncology indications outside these territories OBT has out-licensed OBT076 to Menarini.
